Sep 28, 2016
Last week’s accelerated approval of Sarepta’s drug, Exondys 51™ (eteplirsen), for the treatment of a subset of Duchenne Muscular Dystrophy (“DMD”) patients, was an example of the amazing promise, and associated volatility within the biotech industry. We, at Locust...
Sep 21, 2016
While they sound similar, “stock” vs. “asset” purchase agreements are very different in nature and have meaningful implications for company management, boards and investors. At Locust Walk, we work with myriad small, single-product companies that are looking for help...
Sep 14, 2016
There are new concerns arising in Japan around drug pricing. Last April, the Japanese government introduced a re-pricing rule for “huge seller drugs” and proceeded to slash the reimbursement price for Gilead’s Solvaldi by a hefty 30%. The concern now among industry...
Sep 8, 2016
Article appearing in “The Huffington Post” about Geoff Meyerson, Managing Partner and Co-Founder and Locust Walk business. Convergence is when several people or things come together from different directions so as to eventually meet. Way up on the 18th...
Sep 8, 2016
When a deal process is begun, the initial focus is on identifying good potential partners and getting them engaged in preliminary discussions. As one or more potential partners advance beyond these early discussions, the process moves into the critical due diligence...
